Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Chataway

Showing results (1-10 of 182) with videos related to

Pageof 19
Sort By:
The Lancet. Neurology|February 8, 2018
Evolving diagnostic criteria for multiple sclerosisJeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2016
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YESJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2010
Progression is likely to occur earlier in young men with motor onset symptomsJeremy Chataway
Practical Neurology|September 23, 2010
When confronted by a patient with the radiologically isolated syndromeJeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2014
Oral versus intravenous steroids in multiple sclerosis relapses - a perennial question?Jeremy Chataway
Lancet (London, England)|September 16, 2014
Simvastatin in patients with progressive multiple sclerosis--Authors' replyJeremy Chataway,
The Lancet. Neurology|May 21, 2018
Tackling progression in multiple sclerosisJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2017
Treating clinically isolated syndrome: the long gameJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2008
When the MRI scan suggests multiple sclerosis but the symptoms do notJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|March 14, 2012
Treating multiple sclerosis with vitamin DJeremy Chataway
Pageof 19

Showing results (1-10 of 182) with videos related to

Sort By:
Pageof 19
The Lancet. Neurology|February 8, 2018
Evolving diagnostic criteria for multiple sclerosisJeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 13, 2016
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YESJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2010
Progression is likely to occur earlier in young men with motor onset symptomsJeremy Chataway
Practical Neurology|September 23, 2010
When confronted by a patient with the radiologically isolated syndromeJeremy Chataway
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2014
Oral versus intravenous steroids in multiple sclerosis relapses - a perennial question?Jeremy Chataway
Lancet (London, England)|September 16, 2014
Simvastatin in patients with progressive multiple sclerosis--Authors' replyJeremy Chataway,
The Lancet. Neurology|May 21, 2018
Tackling progression in multiple sclerosisJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2017
Treating clinically isolated syndrome: the long gameJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2008
When the MRI scan suggests multiple sclerosis but the symptoms do notJeremy Chataway
Journal of Neurology, Neurosurgery, and Psychiatry|March 14, 2012
Treating multiple sclerosis with vitamin DJeremy Chataway
Pageof 19